This is the authors' abstract. We don't add key points for this paper.
The combination of bedaquiline, pretomanid, and linezolid led to a favorable outcome at 6 months after the end of therapy in a high percentage of patients with highly drug-resistant forms of tuberculosis; some associated toxic effects were observed. (Funded by the TB Alliance and others; ClinicalTrials.gov number, NCT02333799.).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Conradie et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: